Zhejiang Mingpai Industrial Co., Ltd. has decided to terminate its plan to reduce its stake in Caibai Co., Ltd., having not sold any shares. Concurrently, Shun Jing Pharmaceutical, a subsidiary of Rejebio, has received approval from China's National Medical Products Administration for a clinical trial of its innovative drug SGC001 injection. This drug, previously approved by the FDA and CDE for acute myocardial infarction treatment, will now also be investigated for severe acute pancreatitis. AI
RANK_REASON The cluster contains multiple unrelated news items, including a shareholder's decision to terminate a stake reduction plan and a subsidiary's drug trial approval, presented in a digest format.
- Caibai Co., Ltd.
- National Medical Products Administration
- Rejebio
- SGC001 injection
- Shun Jing Pharmaceutical
- FDA
- Zhejiang Mingpai Industrial Co., Ltd.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →